AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX’s Brown A...
March 10 2021 - 8:00AM
Business Wire
- Research to utilize AgeX’s proprietary BAT cellular product
candidate AgeX-BAT1.
- Loss of non-shivering thermogenic BAT, also known as brown or
good fat, in humans with aging is associated with obesity, type II
diabetes, and cardiovascular disease.
- Studies to evaluate if transplantation of AgeX-BAT1 in mice
improves diet-induced obesity, metabolic health including glucose
metabolism, and cardiac function.
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a
biotechnology company developing therapeutics for human aging and
regeneration, announced today a research collaboration with The
Ohio State University using AgeX’s brown adipocyte tissue (BAT)
cell therapy candidate AgeX-BAT1 in mice to determine whether
transplantation of AgeX-BAT1 cells may improve diet-induced
obesity, metabolic health including glucose metabolism, and cardiac
function.
The research will be conducted in the laboratory of
world-leading BAT researcher Kristin Stanford, Ph.D., Associate
Professor in Physiology & Cell Biology and Associate Director
of the Diabetes and Metabolism Research Center at The Ohio State
University Wexner Medical Center. As an early pioneer in BAT
transplantation, Dr. Stanford transplanted BAT from donor mice into
recipient mice. By 8–12 weeks post transplantation, recipient mice
had improved glucose tolerance, increased insulin sensitivity,
lower body weight, reduced fat mass, and a full reversal of
high-fat diet-induced insulin resistance (J Clin Invest
2013;123:215-23). This year, Dr. Stanford became the first person
to show a direct role for BAT to enhance cardiac function
(Circulation 2021;143:145-159).
“We will be investigating the potential of human pluripotent
stem cell-derived brown adipose tissue (BAT) to improve metabolic
health and cardiac function,” said Dr. Stanford. “The preclinical
research studies may provide the basis for future therapeutic
interventions in diabetes and obesity as well as provide new
insights into the role of BAT.”
AgeX’s BAT cells may have advantages over other sources of BAT
given published data show that AgeX’s pioneering PureStem® cell
derivation and manufacturing technology platform is able to
generate highly pure and scalable BAT cells, potentially providing
an unlimited source of cells (Stem Cell Res Ther 2019;10:7).
AgeX-BAT1 consists of BAT progenitor cells that are capable of
becoming BAT.
“We are delighted to collaborate with Dr. Kristin Stanford, who
has dedicated her career to understanding brown adipose tissue
(BAT). The research could generate proof-of-concept data in an
animal model for AgeX’s BAT cell therapy candidate AgeX-BAT1,” said
Dr. Nafees Malik, Chief Operating Officer of AgeX. “AgeX’s BAT
cells may offer an innovative therapeutic strategy for diabetes and
obesity, which present potential multi-billion-dollar market
opportunities, given 13% of adults in the U.S. suffer from diabetes
and 42% from obesity.”
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly-defined, universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a variety of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for Type II diabetes. AgeX’s revolutionary
longevity platform induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AgeX is developing its core
product pipeline for use in the clinic to extend human healthspan
and is seeking opportunities to establish licensing and
collaboration agreements around its broad IP estate and proprietary
technology platforms.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, LinkedIn, Facebook, and YouTube.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of AgeX Therapeutics, Inc. and its subsidiaries
particularly those mentioned in the cautionary statements found in
more detail in the “Risk Factors” section of AgeX’s Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q filed with the
Securities and Exchange Commissions (copies of which may be
obtained at www.sec.gov). Further, in the case of AgeX’s new
AgeX-BAT1 arrangement with The Ohio State University, there can be
no assurance that: (i) the outcome of the research will demonstrate
that transplantation of AgeX-BAT1 cells may improve diet-induced
obesity, metabolic health including glucose metabolism, and cardiac
function, (ii) AgeX-BAT1 cells derived for therapeutic use will be
shown to be safe and effective in clinical trials, and (iii) that
if any AgeX-BAT1 cells are derived for therapeutic use, those cells
will be successfully commercialized even if clinical trials are
successful. Subsequent events and developments may cause these
forward-looking statements to change. AgeX specifically disclaims
any obligation or intention to update or revise these
forward-looking statements as a result of changed events or
circumstances that occur after the date of this release, except as
required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210310005228/en/
Contact for AgeX: Dr. Nafees Malik Chief Operating
Officer nmalik@agexinc.com
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Apr 2023 to Apr 2024